FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387169311> ?p ?o ?g. }

• W4387169311 endingPage "s5" @default.
• W4387169311 startingPage "s5" @default.
• W4387169311 abstract "Background: Antibiotics alone are often insufficient to treat recurrent C. difficile infection (rCDI) because they have no activity against C. difficile spores that germinate within a disrupted microbiome. SER-109, an investigational, oral, microbiome therapeutic comprised of purified Firmicutes spores, was designed to reduce rCDI through microbiome repair. We report an integrated efficacy analysis through week 24 for SER-109 from phase 3 studies, ECOSPOR III and ECOSPOR IV. Methods: ECOSPOR III was a randomized, placebo-controlled phase 3 trial conducted at 56 US or Canadian sites that included 182 participants with ≥2 CDI recurrences, confirmed via toxin EIA testing. Participants were stratified by age (<65 years or ≥65 years) and antibiotic regimen (vancomycin, fidaxomicin) and were randomized 1:1 to placebo or SER-109 groups. ECOSPOR IV was an open-label, single-arm study conducted at 72 US or Canadian sites including 263 participants with rCDI enrolled in 2 cohorts: (1) rollover participants from ECOSPOR III who experienced on-study recurrence diagnosed by toxin EIA (n = 29) and (2) participants with ≥1 CDI recurrence (diagnosed by PCR or toxin EIA), inclusive of the current episode (n = 234). In both studies, the investigational product was administered orally as 4 capsules over 3 consecutive days following symptom resolution after standard-of-care antibiotics. The primary efficacy end point was rCDI (recurrent toxin-positive diarrhea requiring treatment) through week 8. Other end points included CDI recurrence rates and safety through 24 weeks. Results: These 349 participants received at least 1 dose of SER-109 in ECOSPOR III or ECOSPOR IV (mean age 64.2; 68.8% female). Overall, 77 participants (22.1%) enrolled with their first CDI recurrence. Four participants received blinded SER-109 in ECOSPOR III followed by a second dose of open-label SER-109 in ECOSPOR IV. Overall, the proportion of participants who received any dose of SER-109 with rCDI at week 8 was 9.5% (33 of 349; 95% CI, 6.6 %–13.0%), and the CDI recurrence rate remained low through 24 weeks (15.2%, 53 of 349; 95% CI, 11.6%–19.4%), corresponding to sustained clinical response rates of 90.5% (95% CI, 87.0%–93.4%) and 84.8% (95% CI, 80.6%–88.4%), respectively (Fig. 1). Most rollover participants (25 of 29, 86.2%) were from the placebo arm; 13.8% had rCDI by week 8. Conclusions: In this integrated analysis, the rates of rCDI were low and durable in participants who received the investigational microbiome therapeutic SER-109, with sustained clinical response rates of 90.5% and 84.8% at weeks 8 and 24, respectively. These data further support the potential benefit of microbiome repair with SER-109 following antibiotics for rCDI to prevent recurrence in high-risk patients. Financial support: This study was funded by Seres Therapeutics. Disclosure: None" @default.
• W4387169311 created "2023-09-30" @default.
• W4387169311 creator A5002574698 @default.
• W4387169311 creator A5003227513 @default.
• W4387169311 creator A5007426598 @default.
• W4387169311 creator A5009499028 @default.
• W4387169311 creator A5016245381 @default.
• W4387169311 creator A5021420574 @default.
• W4387169311 creator A5024258790 @default.
• W4387169311 creator A5025652958 @default.
• W4387169311 creator A5032718952 @default.
• W4387169311 creator A5036787987 @default.
• W4387169311 creator A5039392793 @default.
• W4387169311 creator A5048598581 @default.
• W4387169311 creator A5056182319 @default.
• W4387169311 creator A5059739934 @default.
• W4387169311 creator A5061887507 @default.
• W4387169311 creator A5065767678 @default.
• W4387169311 creator A5070267539 @default.
• W4387169311 creator A5070512771 @default.
• W4387169311 creator A5070773342 @default.
• W4387169311 creator A5071093411 @default.
• W4387169311 date "2023-06-01" @default.
• W4387169311 modified "2023-09-30" @default.
• W4387169311 title "Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent <i>Clostridioides difficile</i> infection" @default.
• W4387169311 doi "https://doi.org/10.1017/ash.2023.214" @default.
• W4387169311 hasPublicationYear "2023" @default.
• W4387169311 type Work @default.
• W4387169311 citedByCount "0" @default.
• W4387169311 crossrefType "journal-article" @default.
• W4387169311 hasAuthorship W4387169311A5002574698 @default.
• W4387169311 hasAuthorship W4387169311A5003227513 @default.
• W4387169311 hasAuthorship W4387169311A5007426598 @default.
• W4387169311 hasAuthorship W4387169311A5009499028 @default.
• W4387169311 hasAuthorship W4387169311A5016245381 @default.
• W4387169311 hasAuthorship W4387169311A5021420574 @default.
• W4387169311 hasAuthorship W4387169311A5024258790 @default.
• W4387169311 hasAuthorship W4387169311A5025652958 @default.
• W4387169311 hasAuthorship W4387169311A5032718952 @default.
• W4387169311 hasAuthorship W4387169311A5036787987 @default.
• W4387169311 hasAuthorship W4387169311A5039392793 @default.
• W4387169311 hasAuthorship W4387169311A5048598581 @default.
• W4387169311 hasAuthorship W4387169311A5056182319 @default.
• W4387169311 hasAuthorship W4387169311A5059739934 @default.
• W4387169311 hasAuthorship W4387169311A5061887507 @default.
• W4387169311 hasAuthorship W4387169311A5065767678 @default.
• W4387169311 hasAuthorship W4387169311A5070267539 @default.
• W4387169311 hasAuthorship W4387169311A5070512771 @default.
• W4387169311 hasAuthorship W4387169311A5070773342 @default.
• W4387169311 hasAuthorship W4387169311A5071093411 @default.
• W4387169311 hasBestOaLocation W43871693111 @default.
• W4387169311 hasConcept C126322002 @default.
• W4387169311 hasConcept C141071460 @default.
• W4387169311 hasConcept C142724271 @default.
• W4387169311 hasConcept C143121216 @default.
• W4387169311 hasConcept C168563851 @default.
• W4387169311 hasConcept C203092338 @default.
• W4387169311 hasConcept C204787440 @default.
• W4387169311 hasConcept C27081682 @default.
• W4387169311 hasConcept C2778980435 @default.
• W4387169311 hasConcept C2779489039 @default.
• W4387169311 hasConcept C2779802037 @default.
• W4387169311 hasConcept C2781342628 @default.
• W4387169311 hasConcept C2781413609 @default.
• W4387169311 hasConcept C2910067853 @default.
• W4387169311 hasConcept C2994496256 @default.
• W4387169311 hasConcept C501593827 @default.
• W4387169311 hasConcept C523546767 @default.
• W4387169311 hasConcept C54355233 @default.
• W4387169311 hasConcept C60644358 @default.
• W4387169311 hasConcept C71924100 @default.
• W4387169311 hasConcept C86803240 @default.
• W4387169311 hasConcept C89423630 @default.
• W4387169311 hasConcept C90924648 @default.
• W4387169311 hasConcept C97505648 @default.
• W4387169311 hasConceptScore W4387169311C126322002 @default.
• W4387169311 hasConceptScore W4387169311C141071460 @default.
• W4387169311 hasConceptScore W4387169311C142724271 @default.
• W4387169311 hasConceptScore W4387169311C143121216 @default.
• W4387169311 hasConceptScore W4387169311C168563851 @default.
• W4387169311 hasConceptScore W4387169311C203092338 @default.
• W4387169311 hasConceptScore W4387169311C204787440 @default.
• W4387169311 hasConceptScore W4387169311C27081682 @default.
• W4387169311 hasConceptScore W4387169311C2778980435 @default.
• W4387169311 hasConceptScore W4387169311C2779489039 @default.
• W4387169311 hasConceptScore W4387169311C2779802037 @default.
• W4387169311 hasConceptScore W4387169311C2781342628 @default.
• W4387169311 hasConceptScore W4387169311C2781413609 @default.
• W4387169311 hasConceptScore W4387169311C2910067853 @default.
• W4387169311 hasConceptScore W4387169311C2994496256 @default.
• W4387169311 hasConceptScore W4387169311C501593827 @default.
• W4387169311 hasConceptScore W4387169311C523546767 @default.
• W4387169311 hasConceptScore W4387169311C54355233 @default.
• W4387169311 hasConceptScore W4387169311C60644358 @default.
• W4387169311 hasConceptScore W4387169311C71924100 @default.
• W4387169311 hasConceptScore W4387169311C86803240 @default.
• W4387169311 hasConceptScore W4387169311C89423630 @default.
• W4387169311 hasConceptScore W4387169311C90924648 @default.

• next